CN111995745B - 一种双锁型聚合物及其制备方法和应用 - Google Patents

一种双锁型聚合物及其制备方法和应用 Download PDF

Info

Publication number
CN111995745B
CN111995745B CN202010861678.4A CN202010861678A CN111995745B CN 111995745 B CN111995745 B CN 111995745B CN 202010861678 A CN202010861678 A CN 202010861678A CN 111995745 B CN111995745 B CN 111995745B
Authority
CN
China
Prior art keywords
cells
peg
val
fmoc
cit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010861678.4A
Other languages
English (en)
Other versions
CN111995745A (zh
Inventor
袁友永
郑锐
宗庆瑜
肖炫
姜茂麟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
South China University of Technology SCUT
Original Assignee
South China University of Technology SCUT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by South China University of Technology SCUT filed Critical South China University of Technology SCUT
Priority to CN202010861678.4A priority Critical patent/CN111995745B/zh
Publication of CN111995745A publication Critical patent/CN111995745A/zh
Application granted granted Critical
Publication of CN111995745B publication Critical patent/CN111995745B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3322—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof acyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33303—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group
    • C08G65/33306—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group acyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/3332—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing carboxamide group
    • C08G65/33327—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing carboxamide group cyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
    • C08G65/3348—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing nitrogen in addition to sulfur

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明公开了一种双锁型聚合物及其制备方法和应用。本发明的双锁型聚合物的结构式为：
Figure DDA0002648350220000011
式中，x为110～117的自然数，y为70～80的自然数，z为1～3的自然数。本发明的双锁型聚合物具有良好的生物相容性和可降解性，由其自组装形成的纳米颗粒可以用于肿瘤成像与治疗。

Description

一种双锁型聚合物及其制备方法和应用
技术领域
本发明涉及聚合物荧光探针技术领域，具体涉及一种双锁型聚合物及其制备方法和应用。
背景技术
光学成像是以发光探针的发光强度为检测信号的可视化成像技术，主要包括生物发光技术和荧光技术，已经广泛应用于癌症的早期、准确诊断。激活型荧光探针可以对肿瘤微环境发出响应信号，具有较低的背景噪声和较高的信号-背景比，能对肿瘤进行灵敏、准确的诊断，效果要显著优于“常开”光学探针。
近年来，随着前体药物和纳米技术在药物传递领域的广泛应用，极大地丰富了抗肿瘤药物的传递策略，而基于小分子前药的自组装纳米递送系统结合了前体药物策略和纳米技术的优点，载药量高、稳定性好、毒副作用小，成为了研究的热点。无论是前药还是纳米给药系统，智能地触发药物在靶点的选择性释放对制剂的有效性和安全性都非常重要。与正常细胞相比，肿瘤细胞特殊的微环境已被广泛应用于设计刺激反应药物传递系统。
目前，大多数用于癌症成像和治疗的纳米材料都可能对健康组织造成非特异性背景和毒性，并引起严重的副作用。为了提高特异性，许多对癌症特异性生物标志物(如低pH值、过表达酶或谷胱甘肽)有反应的刺激反应纳米材料已经被开发用于癌症成像和治疗，但大多数刺激反应型纳米材料仅对单一刺激产生反应，可能并不足以区分肿瘤组织，并会导致成像的高背景信号和治疗的副作用。为了改善位点的特异性转运和降低非靶标细胞的毒性，开发能够对多种癌症相关生物标志物共存做出反应的智能纳米材料是非常可取的。然而，开发能够同时对正交刺激做出反应，并具有集成的成像和治疗功能的纳米探针仍是一项挑战。
发明内容
本发明的目的在于提供一种双锁型聚合物及其制备方法和应用。
本发明所采取的技术方案是：
一种双锁型聚合物，结构式为：
Figure BDA0002648350200000021
式中，x为110～117的自然数，y为70～80的自然数，z为1～3的自然数。
上述双锁型聚合物的制备方法，包括以下步骤：
1)进行二异丙基乙醇胺和甲基丙烯酰氯的反应，得到2-(二异丙基氨基)甲基丙烯酸乙酯；
2)进行甲氧基聚乙二醇和4-氰基-4-(硫代苯甲硫基)戊酸的酯化反应，得到
Figure BDA0002648350200000022
即PEG-CPDB；
3)进行PEG-CPDB、2-(二异丙基氨基)甲基丙烯酸乙酯和甲基丙烯酸的聚合反应，得到
Figure BDA0002648350200000023
即PEG-b-(PDPA-co-MAA)；
4)进行
Figure BDA0002648350200000024
和L-瓜氨酸的反应，得到
Figure BDA0002648350200000025
即Fmoc-Val-Cit；
5)进行
Figure BDA0002648350200000026
和Fmoc-Val-Cit的反应，得到
Figure BDA0002648350200000031
即Fmoc-Val-Cit-NH-Cy；
6)Fmoc-Val-Cit-NH-Cy转化成
Figure BDA0002648350200000032
7)进行PEG-b-(PDPA-co-MAA)和
Figure BDA0002648350200000033
的反应，得到
Figure BDA0002648350200000034
优选的，步骤1)所述二异丙基乙醇胺、甲基丙烯酰氯的摩尔比为1：(1.0～1.2)。
优选的，步骤1)所述反应的时间为20～30h。
优选的，步骤2)所述甲氧基聚乙二醇、4-氰基-4-(硫代苯甲硫基)戊酸的摩尔比为1：(4～5)。
优选的，步骤2)所述酯化反应的时间为40～70h。
优选的，步骤3)所述PEG-CPDB、2-(二异丙基氨基)甲基丙烯酸乙酯、甲基丙烯酸的摩尔比为1：(80～90)：(3～4)。
优选的，步骤3)所述聚合反应的时间为10～20h。
优选的，步骤4)所述
Figure BDA0002648350200000041
L-瓜氨酸的摩尔比为1：(1.6～1.8)。
优选的，步骤4)所述反应的时间为10～20h。
优选的，步骤5)所述
Figure BDA0002648350200000042
Fmoc-Val-Cit的摩尔比为1：(2.5～3.0)。
优选的，步骤5)所述反应的时间为15～25h。
优选的，步骤7)所述PEG-b-(PDPA-co-MAA)、
Figure BDA0002648350200000043
的摩尔比为1：(1～3)。
优选的，步骤7)所述反应的时间为20～30h。
本发明的有益效果是：本发明的双锁型聚合物具有良好的生物相容性和可降解性，由其自组装形成的纳米颗粒可以用于肿瘤成像与治疗。
具体来说：
本发明的双锁型聚合物自组装形成的纳米颗粒，在肿瘤细胞内的内涵体/溶酶体酸性环境中会通过质子化使颗粒内核由疏水性向亲水性转变，颗粒崩解，使小分子肽和荧光分子连接键暴露出来，并且在溶酶体内组织蛋白酶B的作用下，连接键断裂，荧光分子Cy-NH2释放出来，小分子Cy-NH2不仅可以荧光成像，而且能够靶向至肿瘤细胞线粒体，使线粒体活性氧上升，ATP下降，从而杀死肿瘤细胞，达到诊疗一体的目的，具有巨大的临床应用潜能。
附图说明
图1为实施例中的S-PPDPA-VC-Cy的合成路线图。
图2为实施例中的PEG-CPDB的核磁共振氢谱图。
图3为实施例中的PEG-b-(PDPA-co-MAA)的核磁共振氢谱图。
图4为实施例中的Fmoc-Val-Cit-NH-Cy的核磁共振氢谱图。
图5为实施例中的S-PPDPA-VC-Cy的核磁共振氢谱图。
图6为对比例中的inS-PPDPA-VC-Cy的合成路线图。
图7为对比例中的inS-PPDPA-VC-Cy的核磁共振氢谱图。
图8为纳米颗粒在水溶液中的粒径及粒径分布图。
图9为纳米颗粒在酸性条件下和中性条件下酶作用后的荧光光谱图。
图10为S-NP在酸性条件下酶作用不同时间后的荧光光谱图。
图11为S-NP和inS-NP在不同pH环境下酶作用后的荧光光谱图。
图12为S-NP和inS-NP对4T1细胞杀伤效果实验图。
图13为流式检测细胞摄取两种纳米颗粒后细胞凋亡情况图。
图14为激光共聚焦观察4T1细胞和MEF细胞摄取纳米颗粒后的荧光恢复情况图。
图15为激光共聚焦观察肿瘤细胞摄取纳米颗粒后荧光分子的胞内分布情况图。
图16为激光共聚焦观察肿瘤细胞摄取纳米颗粒后胞内ROS和ATP水平情况图。
图17为小动物活体成像情况图。
具体实施方式
下面结合具体实施例对本发明做进一步的解释和说明。
Cy-NH2：参照“Activity-Based Near-Infrared Fluorogenic Probe forEnabling in Vitroand in Vivo Profiling of Neutrophil Elastase，Anal.Chem.2019,91,3877-3884”制备。
Fmoc-Val-NHS：参照“Cathepsin B-Labile Dipeptide Linkers for LysosomalRelease of Doxorubicin from Internalizing Immunoconjugates:Model Studies ofEnzymatic Drug Release and Antigen-Specific In Vitro Anticancer Activity，Bioconjugate Chem.2002,13,855-869”制备。
实施例：
一种双锁型聚合物S-PPDPA-VC-Cy(合成路线图见图1)，其制备方法包括以下步骤：
1)将0.1mol的二异丙基乙醇胺、0.1mol的三乙胺和0.001mol的对苯二酚分散在100mL的四氢呋喃中，再滴加0.1mol的甲基丙烯酰氯，滴加完后在氩气气氛下室温搅拌反应24h，过滤除去沉淀的三乙胺盐酸盐，旋转蒸发除去四氢呋喃，85℃真空(0.05mmHg)蒸馏，得到2-(二异丙基氨基)甲基丙烯酸乙酯(无色液体)；
2)将0.4mmol的mPEG114分散在20mL的无水二氯甲烷中，再加入1.6mmol的4-氰基-4-(硫代苯甲硫基)戊酸和0.2mmol的4-二甲基氨基吡啶，再在冰浴下滴加10mL的二环己基碳二亚胺的二氯甲烷溶液(含二环己基碳二亚胺1.6mmol)，滴加完后室温搅拌反应48h，减压浓缩，用乙醚沉淀3次，得到
Figure BDA0002648350200000061
(PEG-CPDB，核磁共振氢谱如图2所示)；
3)将0.1mmol的PEG-CPDB、8mmol的2-(二异丙基氨基)甲基丙烯酸乙酯(DPA)和0.02mmol的偶氮二异丁腈分散在5mL的1,4-二氧六环中，60℃反应12h，再加入0.3mmol的甲基丙烯酸，继续反应12h，将产物先后用二甲基甲酰胺和纯水透析，再冷冻干燥，得到
Figure BDA0002648350200000062
(PEG-b-(PDPA-co-MAA)，核磁共振氢谱如图3所示)；
4)将0.033mol的L-瓜氨酸和3.24mmol的NaHCO3分散在60mL的水中，再加入由0.02mol的
Figure BDA0002648350200000063
(Fmoc-Val-NHS)、60mL的二甲醚和39mL的四氢呋喃组成的混合溶液，搅拌反应16h，再边搅拌边加入103mL质量分数15％的柠檬酸水溶液，反应混合物用2-丙醇/乙酸乙酯(100mL，2-丙醇的质量分数为10％)萃取3次，有机层用水(100mL)洗涤2次，用无水MgSO4干燥，将有机层蒸发至干，得到
Figure BDA0002648350200000064
(Fmoc-Val-Cit，白色粉末状，收率84％)；
5)将0.22mmol的Fmoc-Val-Cit和0.34mmol的2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU)分散在10mL的二甲基甲酰胺中，再加入0.16mmol的N,N-二异丙基乙胺，室温搅拌反应2h，再加入5mL的
Figure BDA0002648350200000065
(Cy-NH2)的二甲基甲酰胺溶液(含0.088mmol的Cy-NH2)，室温搅拌反应16h，减压除去溶剂，再将粗产物通过硅胶柱色谱法纯化，得到
Figure BDA0002648350200000071
(Fmoc-Val-Cit-NH-Cy，收率40％，核磁共振氢谱如图4所示)；
6)将600μL的无水哌啶加入2mL的Fmoc-Val-Cit-NH-Cy的二甲基甲酰胺溶液(含0.02mmol的Fmoc-Val-Cit-NH-Cy)中，在氩气气氛下室温搅拌反应2h，得到
Figure BDA0002648350200000072
7)将0.02mmol的PEG-b-(PDPA-co-MAA)、0.024mmol的1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐和0.02mmol的N-羟基琥珀酰亚胺分散在2mL的二甲基甲酰胺中，再将得到的混合液加入步骤6)的反应液中，室温反应24h，将产物先后用二甲基甲酰胺和纯水透析，再冷冻干燥，得到
Figure BDA0002648350200000073
(S-PPDPA-VC-Cy，核磁共振氢谱图如图5所示)。
对比例：
一种双锁型聚合物inS-PPDPA-VC-Cy(合成路线图见图6)，其制备方法包括以下步骤：
将步骤1)中的“二异丙基乙醇胺”替换成“异戊醇”进行反应，其余同实施例1，得到
Figure BDA0002648350200000081
(inS-PPDPA-VC-Cy，核磁共振氢谱如图7所示)。
性能测试：
一、纳米颗粒的制备：
通过纳米沉淀法制备纳米颗粒，具体方法如下：
将10mg的S-PPDPA-VC-Cy分散在1mL的四氢呋喃中，再边搅拌边滴加10mL的超纯水，滴加完后搅拌2h，将得到的颗粒溶液转移到透析袋(MWCO 7000)中，在超纯水中透析24h除去四氢呋喃，再将颗粒溶液用0.45μm过滤器过滤，得到的纳米颗粒标记为S-NP。同样，将S-PPDPA-VC-Cy替换成inS-PPDPA-VC-Cy，经过相同的制备过程得到的纳米颗粒标记为inS-NP。
二、双锁型聚合物S-PPDPA-VC-Cy的酸响应性：
纳米颗粒的酸响应：
将S-NP和inS-NP分别加入pH＝5.0、5.5、6.0、6.5、6.8、7.4的0.2mol/L的PBS缓冲液(模拟内涵体/溶酶体酸性微环境)中，孵育培养10min，测试纳米颗粒在水溶液中的粒径及粒径分布，测试结果如图8所示。
由图8可知：随着pH的下降S-NP的尺寸减小到10nm左右，而inS-NP的尺寸变化很小。
三、双锁型聚合物S-PPDPA-VC-Cy的体外荧光光谱：
1)纳米颗粒在酸性条件下和中性条件下酶作用后的荧光光谱：
将S-NP和inS-NP分别加入pH＝5.5和pH＝7.4的0.2mol/L的PBS缓冲液(模拟内涵体/溶酶体酸性微环境)中，并加入木瓜蛋白酶(2μM)，孵育培养12h，S-NP和inS-NP在酸性条件下酶作用后的荧光光谱图如图9所示。
由图9可知：S-NP在酸性条件下酶作用后有明显的荧光恢复，而中性条件下未有荧光恢复，并且在相同条件下inS-NP不存在荧光恢复。
2)纳米颗粒在酸性条件下酶作用不同时间后的荧光光谱：
将S-NP加入pH＝5.5的0.2mol/L的PBS缓冲液(模拟内涵体/溶酶体酸性微环境)中，并加入木瓜蛋白酶(6μM)，孵育培养0、0.5h、1.0h、1.5h、2.0h、2.5h、3.0h、3.5h、4.0h，S-NP在酸性环境中酶作用不同时间后的荧光光谱图如图10所示。
由图10可知：S-NP在酸性条件随着酶作用后时间的延长，荧光逐渐增强。
3)纳米颗粒在不同pH条件下酶作用后的荧光光谱：
将S-NP和inS-NP分别加入pH＝5.0、5.5、6.0、6.5、6.8、7.4的0.2mol/L的PBS缓冲液(模拟内涵体/溶酶体酸性微环境)中，并加入木瓜蛋白酶(2μM)，孵育培养12h，S-NP和inS-NP在不同pH环境下酶作用后的荧光光谱图如图11所示。
由图11可知：S-NP在酸性条件下酶作用后有明显的荧光恢复，而中性条件下未有荧光恢复，并且在相同条件下inS-NP不存在荧光恢复。
四、双锁型聚合物的体外细胞实验：
1)S-NP和inS-NP对小鼠乳腺癌细胞(4T1)和小鼠成纤维细胞(MEF)的杀伤效果实验：
将MEF或4T1细胞接种于96孔组织培养板(1×104细胞/孔)中培养12h，然后在所需的Cy-NH2、Val-Cit-NH-Cy、S-NP或inS-NP浓度下培养细胞，培养24h后用标准的商用甲基噻唑四唑蓝(MTT)法测定细胞活性；流式细胞术分析细胞凋亡；4T1细胞(每孔1×105细胞)在24孔培养板上培养12h，然后用PBS、Cy-NH2、Cy-NH2+Vc(维生素C)、S-NP、S-NP+Vc、S-NP+inhibitor(CA-074组织蛋白酶B抑制剂)、inS-NP、inS-NP+inhibitor等剂量(Cy-NH2：6μg/mL，抑制剂：10mM，Vc:50μM)处理4T1细胞6h；使用膜联蛋白V FITC和碘化丙啶的死细胞凋亡试剂盒(KeyGEN BioTECH，中国)检测细胞凋亡水平；最后，将细胞用PBS缓冲液洗涤3次，收集并通过流式细胞术分析，S-NP和inS-NP对4T1细胞杀伤效果实验图和流式检测细胞摄取两种纳米颗粒后细胞凋亡情况图分别如图12和图13所示。
由图12和图13可知：在7个浓度梯度下，游离的Cy-NH2对4T1和MEF细胞的杀伤效果最强，但是相对于正常细胞，Cy-NH2对肿瘤细胞的杀伤效果更好，另外S-NP对肿瘤细胞的杀伤效果比inS-NP的效果更好，对正常细胞MEF的杀伤效果较弱；流式结果与MTT结果一致。
2)激光共聚焦观察肿瘤细胞摄取纳米颗粒后的荧光恢复实验：
细胞共聚焦荧光成像：将MEF和4T1细胞(每孔2×105细胞)在玻璃盖玻片上培养12h，4T1细胞用S-NP、S-NP+inhibitor、inS-NP、inS-NP+inhibitor等剂量(Cy-NH2：6μg/mL)处理6h，MEF细胞用S-NP、inS-NP等剂量(Cy-NH2：6μg/mL)处理6h；用PBS缓冲液洗涤3次，用4％甲醛溶液固定细胞；最后，用CLSM观察细胞，激光共聚焦观察肿瘤细胞摄取纳米颗粒后的荧光恢复情况图如图14所示。
由图14可知：S-NP经细胞摄取胞内有明显的荧光，而添加了组织蛋白酶抑制剂的组和inS-NP组细胞内无明显的荧光，说明在胞内溶酶体酸性环境和组织蛋白酶B的存在下，S-NP在胞内才会有荧光的恢复。
3)激光共聚焦观察肿瘤细胞摄取纳米颗粒后荧光分子的胞内分布：
将4T1细胞(3×105细胞/孔)在35mm共焦培养皿中培养12h，然后用S-NP(Cy-NH2：6μg/mL)培养4h，然后在37℃下用Lyso-Tracker Green DND-26(150nM)染色2h，线粒体在37℃下用Mito-Tracker Green FM(100nM)染色0.5h，用PBS缓冲液洗涤三次，然后置于无血清的新鲜培养基中，用CLSM观察细胞，激光共聚焦观察肿瘤细胞摄取纳米颗粒后荧光分子的胞内分布情况图如图15所示。
由图15可知：S-NP在经细胞摄取后通过酸性条件和组织蛋白酶B响应后释放出Cy-NH2，Cy-NH2会迅速靶向至线粒体，在细胞线粒体处富集。
4)激光共聚焦观察肿瘤细胞摄取纳米颗粒后胞内活性氧(ROS)和5'-三磷酸腺苷(ATP)水平：
在96孔黑色组织培养板中培养4T1细胞(1×106细胞/孔)，用PBS、Cy-NH2、Cy-NH2+Vc、S-NP、S-NP+Vc、S-NP+inhibitor、inS-NP、inS-NP+inhibitor处理6h，将细胞用PBS缓冲液冲洗3次，然后用2',7'-二氯荧光黄双乙酸盐(DCFH-DA)(20μM)染色，使用微孔板系统(DCF：Ex/Em＝480/525nm)分析ROS水平，激光共聚焦观察肿瘤细胞摄取纳米颗粒后胞内ROS和ATP水平情况图如图16所示。
线粒体膜电位测定：使用JC-1探针评估4T1细胞中的线粒体去极化。将细胞在35mm共聚焦培养皿中培养(3×106个细胞/孔)12h，然后用PBS、Cy-NH2、Cy-NH2+Vc、S-NP、S-NP+Vc、S-NP+inhibitor处理，处理12h后，将细胞与等体积的含JC-1染料(5mg/L)的无血清培养基在37℃下孵育20min。染色结束时，将探针用PBS缓冲液洗涤3次，然后置于无血清的新鲜培养基中。最后，通过CLSM观察细胞。
细胞ATP水平的测量：将4T1细胞(每孔1×106个细胞)在24孔板上培养12h，然后用PBS、Cy-NH2、Cy-NH2+Vc、S-NP、S-NP+Vc、S-处理NP+inhibitor、inS-NP、inS-NP+inhibitor12h。之后，将细胞用PBS缓冲液洗涤3次，在37℃下用胰蛋白酶消化1min，然后加入RPMI1640培养基以终止反应和通过离心收集细胞。使用5'-三磷酸腺苷(ATP)生物发光分析试剂盒和微孔板系统评估ATP水平。
由图16可知：S-NP经细胞摄取以后能够使细胞内的ROS水平上升，胞内ATP的水平下降，通过破坏线粒体膜电位影响细胞活性，最终杀死肿瘤细胞。
五、动物水平实验：
小动物活体成像：
将荷瘤小鼠随机分组(n＝3)，当肿瘤体积达到200mm3时，静脉注射S-NP(Cy-NH2：1.25mg/kg，100μL)，S-NP+inhibitor(Cy-NH2：1.25mg/kg，100μL，抑制剂：5mg/kg，腹腔注射)，inS-NP(Cy-NH2：1.25mg/kg，100μL)，inS-NP+inhibitor(Cy-NH2：1.25mg/kg，100μL，抑制剂：5mg/kg，腹腔注射)。所有小鼠分别于注射前0h、2h、4h、8h、12h、24h和36h，用Xtreme(德国布鲁克)活体荧光仪采集全身荧光图(Ex/Em＝650/700nm)。给药后36h处死小鼠，采集主要脏器(肝、肾、肺、脾、心)和肿瘤组织，进行Cy-NH2分布的离体检测，小动物活体成像情况图如图17所示。
由图17可知：S-NP组可以很好的富集在肿瘤部位，并且其他对照组不能在肿瘤部位有很好的成像效果。
上述实施例为本发明较佳的实施方式，但本发明的实施方式并不受上述实施例的限制，其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化，均应为等效的置换方式，都包含在本发明的保护范围之内。

Claims (9)

1.一种聚合物，其特征在于，结构式为：
Figure FDA0003053576490000011
式中，x为110～117的自然数，y为70～80的自然数，z为1～3的自然数。
2.权利要求1所述的聚合物的制备方法，其特征在于，包括以下步骤：
1)进行二异丙基乙醇胺和甲基丙烯酰氯的反应，得到2-(二异丙基氨基)甲基丙烯酸乙酯；
2)进行甲氧基聚乙二醇和4-氰基-4-(硫代苯甲酰)戊酸的酯化反应，得到
Figure FDA0003053576490000012
即PEG-CPDB；
3)进行PEG-CPDB、2-(二异丙基氨基)甲基丙烯酸乙酯和甲基丙烯酸的聚合反应，得到
Figure FDA0003053576490000013
即PEG-b-(PDPA-co-MAA)；
4)进行
Figure FDA0003053576490000014
和L-瓜氨酸的反应，得到
Figure FDA0003053576490000015
即Fmoc-Val-Cit；
5)进行
Figure FDA0003053576490000016
和Fmoc-Val-Cit的反应，得到
Figure FDA0003053576490000021
即Fmoc-Val-Cit-NH-Cy；
6)Fmoc-Val-Cit-NH-Cy转化成
Figure FDA0003053576490000022
7)进行PEG-b-(PDPA-co-MAA)和
Figure FDA0003053576490000023
的反应，得到
Figure FDA0003053576490000024
3.根据权利要求2所述的制备方法，其特征在于：步骤1)所述二异丙基乙醇胺、甲基丙烯酰氯的摩尔比为1：(1.0～1.2)。
4.根据权利要求2所述的制备方法，其特征在于：步骤2)所述甲氧基聚乙二醇、4-氰基-4-(硫代苯甲酰)戊酸的摩尔比为1：(4～5)。
5.根据权利要求2所述的制备方法，其特征在于：步骤3)所述PEG-CPDB、2-(二异丙基氨基)甲基丙烯酸乙酯、甲基丙烯酸的摩尔比为1：(80～90)：(3～4)。
6.根据权利要求2所述的制备方法，其特征在于：步骤4)所述
Figure FDA0003053576490000031
L-瓜氨酸的摩尔比为1：(1.6～1.8)。
7.根据权利要求2所述的制备方法，其特征在于：步骤5)所述
Figure FDA0003053576490000032
Fmoc-Val-Cit的摩尔比为1：(2.5～3.0)。
8.根据权利要求2所述的制备方法，其特征在于：步骤7)所述PEG-b-(PDPA-co-MAA)、
Figure FDA0003053576490000033
的摩尔比为1：(1～3)。
9.权利要求1所述的聚合物用于制备抗肿瘤药物的应用。
CN202010861678.4A 2020-08-25 2020-08-25 一种双锁型聚合物及其制备方法和应用 Active CN111995745B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010861678.4A CN111995745B (zh) 2020-08-25 2020-08-25 一种双锁型聚合物及其制备方法和应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010861678.4A CN111995745B (zh) 2020-08-25 2020-08-25 一种双锁型聚合物及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN111995745A CN111995745A (zh) 2020-11-27
CN111995745B true CN111995745B (zh) 2021-07-20

Family

ID=73471683

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010861678.4A Active CN111995745B (zh) 2020-08-25 2020-08-25 一种双锁型聚合物及其制备方法和应用

Country Status (1)

Country Link
CN (1) CN111995745B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113041361B (zh) * 2021-02-23 2022-08-16 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 一种hdac、ctsl响应的诊疗一体化材料及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105968372A (zh) * 2016-07-08 2016-09-28 苏州大学 一种自发荧光纳米凝胶及其制备方法与应用
CN105963703A (zh) * 2016-07-08 2016-09-28 苏州大学张家港工业技术研究院 一种抗肿瘤药物的制备方法
CN108219510A (zh) * 2018-03-21 2018-06-29 湘潭大学 基于半花菁染料的过氧化亚硝基荧光探针的制备和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105968372A (zh) * 2016-07-08 2016-09-28 苏州大学 一种自发荧光纳米凝胶及其制备方法与应用
CN105963703A (zh) * 2016-07-08 2016-09-28 苏州大学张家港工业技术研究院 一种抗肿瘤药物的制备方法
CN108219510A (zh) * 2018-03-21 2018-06-29 湘潭大学 基于半花菁染料的过氧化亚硝基荧光探针的制备和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"A General Strategy for Macrotheranostic Prodrug Activation: Synergy between the Acidic Tumor Microenvironment and Bioorthogonal Chemistry";Dong Yansong et al.;《Angewandte Chemie-International Edition》;20200427;第59卷(第18期);第7168-7172页 *
"Smart Probe for Tracing Cancer Therapy: Selective Cancer Cell Detection, Image-Guided Ablation, and Prediction of Therapeutic Response In Situ";YuanYouyong et al.;《Small》;20150923;第36卷(第11期);第4682-4690页 *

Also Published As

Publication number Publication date
CN111995745A (zh) 2020-11-27

Similar Documents

Publication Publication Date Title
CN107802840B (zh) 一种基于肽类树形分子修饰荧光碳点的肿瘤微环境响应纳米粒及其制备方法
CN104650194B (zh) 一种肽类树状大分子药物及其制备方法和应用
CN107648618B (zh) 一种药物递送体系及其制备方法与应用
CN109276721A (zh) 一种靶向介孔聚多巴胺多功能纳米诊疗剂及其制备方法与应用
CN106581690B (zh) 肿瘤微环境刺激可降解的两亲性嵌段hpma聚合物给药系统及其制备方法
CN106729735B (zh) 一种pH敏感的多肽聚合物及其制备方法和应用
Sun et al. Acid-breakable TPGS-functionalized and diallyl disulfide-crosslinked nanogels for enhanced inhibition of MCF-7/ADR solid tumours
CN111995745B (zh) 一种双锁型聚合物及其制备方法和应用
CN107625968B (zh) 一种肿瘤特异性组织-细胞双渗透纳米粒、制备方法及其应用
CN106880848B (zh) 可生物降解的多聚HPMA-Gd磁共振成像探针及其制备方法
CN103768612B (zh) 负载阿霉素的peg化肽类树状大分子靶向给药系统及其制备方法
CN114149482B (zh) 一种螯合金属离子的智能转换双重刺激响应型探针及其制备方法和应用
CN106512021A (zh) 负载紫杉醇的不对称树状大分子纳米载药系统及其制备方法
CN114010598A (zh) 基于切伦科夫效应的酸响应纳米胶束及其制备方法和应用
CN112121182A (zh) 一种检测缺氧细胞用纳米探针及其制备方法与应用
CN103768613B (zh) 基于gflg的peg化肽类树状大分子给药系统及其制备方法
CN113797350B (zh) 一种糖基聚合物及其制备方法和用途
CN113786492B (zh) 一种可用于光动力治疗的聚合物载体及其制备方法和用途
Zhang et al. Surface-adaptive nanoparticles with near-infrared aggregation-induced emission for image-guided tumor resection
CN117126670B (zh) 一种硼酸功能化CdTe量子点及肿瘤靶向诊疗一体化复合纳米药物
CN111298140B (zh) 还原响应的t1/t2切换型mri造影剂、其制备方法及应用
CN110279856A (zh) 一种PEG-Peptide光动力-化疗联用给药系统及其制备方法和用途
CN115137818B (zh) 谷胱甘肽激活的光敏剂-化疗药一体化分子前药及其应用
CN107778377A (zh) 四碘甲腺乙酸修饰的壳寡糖硬脂酸嫁接物及制备和应用
CN113041361B (zh) 一种hdac、ctsl响应的诊疗一体化材料及其制备方法与应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant